Co SE (KCO:GR) with a Buy rating and a price target of EUR8.10. The firm's analysts highlight the company's strategic shift towards more promising opportunities in North America and the ...

This year’s rebound in European luxury-goods stocks is missing one notable name.Most Read from BloombergTexas HOA Charged ...

New development aims to offer clients improved execution services on an agency basis across listed derivatives and related financial instruments.

or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Future results may turn out to be materially different from the ...

Under the liquidity contract granted to Kepler Cheuvreux by Inventiva ... or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline ...

Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with MASH, a common and progressive chronic liver ...

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with ...

Bernstein SocGen Group updated its financial outlook on Coca-Cola (NYSE:KO) HBC AG (CCH:LN) (OTC: CCHGY), increasing the ...

Kepler Cheuvreux’s execution division KCx has expanded its execution access to the Middle East and Northern Africa (MENA). KCx’s expansion opens trading opportunities in the following countries: Dubai ...

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with ...